Europe Chronic Cough Market Analysis and Opportunities by 2027

The Chronic Cough market in Europe is expected to grow from US$ 1,647.94 million in 2019 to US$ 2,881.55 million by 2027. This represents a CAGR of 7.3% from 2020 to 2027.

The growth of the market in the region is expected to grow owing to rising incidences of chronic cough, growing product developments to treat chronic cough. Additionally, robust product pipeline, presence of major players and well-developed regulatory policies are projected to drive the Europe n chronic cough market during the forecast period.

The UK has observed fast growth in the chronic cough market within the past few years and is expected to lead the market in Europe during the forecast period. Cough is an essential neurally mediated reflex that has evolved to protect the upper airways from obstruction and to expel chemical and mechanical irritants. However, when heightened or persistent, cough presents a clinically challenging source of considerable physical and psychological morbidity. Acute cough contributes to approximately 34.0 million working days lost each year in the UK through minor illnesses, with more than £100 million being spent on over-the-counter antitussive drugs each year. A recent survey, conducted across 29 different European countries, found that most subjects with chronic cough responded that their cough medication had limited or no effectiveness (57% and 36%, respectively), with only 7% reporting that medications they had tried for their cough were effective. This lack of effective treatment reflects the need for new treatment. Indeed, it is increasingly recognized that to treat cough syndromes effectively; there is a need to look beyond the presence of underlying disease processes, and towards a better understanding of physiological control of the cough reflex itself.

UK Chronic Cough Market Revenue and Forecast to 2027 (US$ Million)

EUROPE CHRONIC COUGH – MARKET SEGMENTATION

By Drug Class

• Antihistamines
• Corticosteroids
• Decongestants
• Combination Drug
• Antibiotics
• Acid Blockers
• Other Drug Class

By Route of Administration

• Oral
• Injections
• Nasal
• Other Route of Administration

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Country

• Germany
• France
• United Kingdom
• Italy
• Spain

Company Profiles

• Novartis AG
• Teva Pharmaceutical Industries Ltd
• GlaxoSmithKline plc.
• Bayer AG
• Mylan N.V.
• Amneal Pharmaceuticals, Inc.
• Cipla Inc.
• Reckitt Benckiser Group plc.
• Sun Pharmaceutical Industries Ltd
• Aurobindo Pharma Ltd

Europe Chronic Cough Report Scope